Beta Bionics Q4 Earnings Call Highlights

Core Insights - Beta Bionics reported significant growth in net sales for 2025, reaching $100.3 million, a 54% increase year-over-year, with Q4 sales at $32.1 million, up 57% year-over-year [2][6] - The company emphasized its strategy to enhance access through pharmacy reimbursement, with new patient starts through pharmacy rising to the high 20s percentage for full-year 2025, compared to a high single-digit percentage in the previous year [1][6] - CEO Sean Saint noted that nearly 20,000 new users adopted the iLet in 2025, more than doubling the installed base to over 35,000 users since launch [2][6] Financial Performance - Beta Bionics achieved a gross margin of 55.4% for 2025, slightly expanding from the prior year, with Q4 gross margin at 59%, an increase of 179 basis points year-over-year [2][7] - The company guided for 2026 revenue between $130 million and $135 million, with a gross margin forecast of 55.5% to 57.5% [10][19] - Operating expenses for Q4 were reported at $35.1 million, up from $24.7 million in Q4 2024, driven by increased sales and marketing efforts and R&D investments [9] Product Pipeline and Development - Progress on the Mint patch pump is on track for an unconstrained commercial launch by the end of 2027, with successful first-in-human feasibility testing of the bihormonal system showing no glucagon safety signals [4][16][17] - Approximately 25% to 30% of Q4 new patient starts were off-label type 2 diabetes users, indicating potential for expanding the product label through the FDA [4][18] - The company is exploring a type 2 label and plans to leverage existing pharmacy relationships for the Mint product coverage [16][18] Regulatory and Compliance - A late-January FDA warning letter highlighted quality-system observations from a June inspection, with the company beginning remediation efforts immediately and expecting compliance by the end of Q2 [5][14][15] - Key areas of concern from the FDA included complaint handling, medical device reporting, and corrective and preventative action practices [15] Market Strategy and Expansion - Management plans to add at least 20 sales territories in 2026, with much of the expansion occurring in the first half of the year [13] - The company reported a modest pull-forward of about $1 million in pharmacy stocking orders from Q1 into Q4 ahead of end-of-year price increases [7] - Approximately 69% of Q4 new patient starts came from individuals previously using multiple daily injections, indicating the iLet's potential to expand the pump market [8]